Cosciens Biopharma (TSX:CSCI) Short Percentage of Float


TSX:CSCI Cosciens Biopharma Inc TSX:CSCI
63 GF Score
Price C$3.24
GF Value C$3.31
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Cosciens Biopharma Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

TSX:CSCI vs VRTX, REGN, ALNY: Short Percentage of Float Comparison

For the Biotechnology subindustry, Cosciens Biopharma's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cosciens Biopharma Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Cosciens Biopharma's Short Percentage of Float falls into.


TSX:CSCI
63GF Score
Cosciens Biopharma Inc TSX:CSCI
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cosciens Biopharma (TSX:CSCI) Overvalued in 2026?

Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be undervalued. The current stock price of C$3.24 is trading 2.1% below its estimated GF Value™ of C$3.31. GuruFocus considers Cosciens Biopharma to be Fairly Valued.

Key valuation signals for TSX:CSCI:

  • Short Percentage of Float:
  • GF Value™: C$3.31 vs. price of C$3.24 (2.1% below fair value)
  • GF Score™: 63/100 with 6 warning signs

No single metric tells the full story. See the TSX:CSCI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cosciens Biopharma Business Description

Other Exchanges CSCIF:USAET8:Germany
Address C/o Borden Ladner Gervais Llp, Suite 3400, 22 Adelaide Street West, Toronto, ON, CAN, M5H 4E3
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
63GF Score

Get the complete analysis for TSX:CSCI

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$3.24
Price
C$3.31
GF Value